XML 48 R11.htm IDEA: XBRL DOCUMENT

Revenue Recognition	3 Months Ended
Revenue Recognition	Sep. 30, 2015
Text Block [Abstract]
Revenue Recognition	Note 5 – Revenue Recognition The $466,000 and $6,000 product and service revenue recognized during the three months ended September 30, 2015 and 2014, respectively, represents sales of our ProstaScint product and the RedoxSYS System. The license revenue recognized in the three months ended 2015 and 2014, respectively, represents the amortization of the upfront payments received from our license agreements. The initial payment of $500,000 from the license agreement of Zertane with a Korean pharmaceutical company was deferred and is being recognized over ten years. The initial payment of $250,000 from the license agreement of Zertane with a Canadian-based supplier was deferred and is being recognized over seven years.